Menu
Recruiting NCT07339852

Implementation and Evaluation of a Pharmacist-led Diabetes Care Pathway in Alberta Community Pharmacies

No phase Interventional Diabetes Mellitus Hypertension Hyperlipidaemia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Pharmacist-led diabetes care pathway.
Who it may be relevant to
Registry conditions: Diabetes Mellitus, Hypertension, Hyperlipidaemia. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Implementation and Evaluation of a Pharmacist-led Diabetes Care Pathway in Alberta Community Pharmacies.

Overview

As of 2024, nine percent of Albertans are living with Type 2 diabetes, which increases their risk for cardiovascular disease, stroke, blindness, and kidney failure. Unfortunately, less than half of patients have controlled Type 2 diabetes. We are well aware of the factors which lead to worsening diabetes, but need to give people more support to help them manage their diabetes. Pharmacists are respected health care professionals who are often easier to see that doctors and can help people with diabetes to stay as healthy as possible. This research project aims to see whether a pharmacist service can help improve diabetes management in people with type 2 diabetes compared to usual care from their family physician or nurse practitionner. The potential impact of this project is to empower people with type 2 diabetes to understand their condition, it's management, and to achieve target blood sugar levels, which will ultimately reduce the risk of diabetes-related complications.

Interventions

  • Other Pharmacist-led diabetes care pathway
    articipants in the intervention arm will receive the care using a shared decision-making pharmacist care pathway approach designed to guide type 2 diabetes management to achieve target A1C levels and reduce the risk of diabetes-related complications. The pharmacist care pathway is modelled after the Canadian Diabetes Association Guidelines22. This pathway (tool) will be built into a computer web-based program and include step-by-step, algorithm-guided patient assessment to achieve target A1C lev

Primary outcome measures

  • A1C change [Time frame: Up to 6 months]
Secondary outcome measures (12)
  • Estimated cardiovascular risk [Time frame: Up to 6 months.]
  • Blood Pressure [Time frame: Up to 6 months.]
  • LDL cholesterol concentration [Time frame: Up to 6 months.]
  • Influenza vaccination [Time frame: Up to 6 months.]
  • Pneumococcal vaccination [Time frame: Up to 6 months]
  • Foot exam [Time frame: Up to 6 months]
  • Eye Exam [Time frame: Up to 6 months.]
  • Renal function screening [Time frame: Up to 6 months.]
  • Vascular Protection [Time frame: Up to 6 months.]
  • Pharmacist prescribed prescription medications [Time frame: Up to 6 months.]
  • Pharmacist provided education on lifestyle factors [Time frame: Up to 6 months]
  • Pharmacist provided education on medications and importance of adherence. [Time frame: Up to 6 months]

Eligibility criteria

Inclusion criteria

  • Individuals aged 18 years or older.
  • Individuals with type 2 diabetes.
  • Individuals with type 2 diabetes not reaching HbA1c target of under 7.0%

Exclusion criteria

  • Individuals with type 1 diabetes, gestational diabetes, or other forms of diabetes that are not type 2 diabetes.
  • Pregnant individuals.
  • Individuals at their HbA1c target (HbA1c under 7.0%) or those with a limited life expectancy, frailty, or lack hypoglycemic awareness (i.e., those with an A1c target above 7.0%) .
  • Individuals unable to provide consent or who are unwilling to attend follow-up visits.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Health services research

Study locations

Canada · 1 center
  • University of Alberta — Edmonton

Identifiers

NCT: NCT07339852 · Pro00145395

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗